Tokyo, April 1 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000057529) titled 'Transition of cancer survivors diagnosed with hereditary tumors' on April 1.
Study Type:
Observational
Primary Sponsor:
Institute - MIYAWAKI Satoko
Condition:
Condition - Cancer
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - Identify transitions of cancer survivors diagnosed with hereditary tumors
Basic objectives2 - Others
Eligibility:
Age-lower limit - 20
years-old
<=
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - 1) The patient has been diagnosed with cancer and more than 4 months have passed since the completion of anticancer drug treatment, surgery, or radiation therapy.
2) The patient has been diagnosed with a hereditary tumor based on a genetic test or clinical diagnosis after being diagnosed with cancer, and it has been less than 6 years since the diagnosis of hereditary tumor.
3) The patient is able to speak Japanese and is aware that he/she is physically able to meet in person or online for a one-hour interview.
Key exclusion criteria - Non
Target Size - 20
Recruitment Status:
Recruitment status - No longer recruiting
Date of protocol fixation - 2022 Year 05 Month 26 Day
Date of IRB - 2022 Year 04 Month 10 Day
Anticipated trial start date - 2022 Year 06 Month 01 Day
Last follow-up date - 2025 Year 03 Month 20 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000065727
Disclaimer: Curated by HT Syndication.
